journal article·2011-03

Application of Gold Nanorods for Plasmonic and Magnetic Imaging of Cancer Cells

Liwei Liu, Hong Ding, Ken-Tye Yong, Indrajit Roy, Wing-Cheung Law, Atcha Kopwitthaya, Rajiv Kumar, Folarin Erogbogbo, Xihe Zhang, Paras N. Prasad

Plasmonics· Volume 6· Issue 1
Publisher page

Abstract

We report the use of biocompatible gold nanorods (GNRs) as multimodal (plasmonic and magnetic) probes for cancer cell labeling in vitro. These multifunctional and multimodal bioconjugates were prepared by replacing cetyltrimethylammonium bromide with a mixture of functionalized PEGylation molecules so that a variety of functionalities (e.g., magnetic resonance imaging agent gadolinium (Gd) and biorecognition molecule transferrin (Tf)) can be easily integrated using simple chemistry. It was shown that Gd incorporation did not interfere with the plasmonic properties of the GNRs and a strong T1 relaxivity was estimated (10.0 mM−1 s−1), which is more than twice that of the clinical MRI agent Gd-DTPA. The large observed T1 relaxivity was possibly due to the huge surface to volume ratio of GNR, which allowed huge amount of amine-terminated molecule to anchor on the surface, coupled with Gd (III) ions for the enhanced relaxation of water protons. Pancreatic cancer cell overexpressing the transferring receptor was served as the in vitro model, and the Tf-mediated uptake was demonstrated and confirmed by dark-field imaging and transmission electron microscopy. More importantly, cell viability (MTS) assay did not reveal any sign of toxicity in these treated cells, suggesting that PEGylated GNRs can serve as a biocompatible, multifunctional, and multimodal platform for variable bio-applications.
Source: expertdata · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. Prasad PN (2003) Wiley-Interscience, New York
2. Prasad PN (2004) Wiley-Interscience, New York
3. Ferrari M (2005) Nat Rev Cancer 5:161–17110.1038/nrc1566 ↗
4. Whitesides GM (2005) Small 1:172–17910.1002/smll.200400130 ↗
5. Lim YT, Noh Y-W, Cho J-H, Han JH, Choi BS, Kwon J, Hong KS, Gokarna A, Cho Y-H, Chung BH (2009) J Am Chem Soc 131:17145–1715410.1021/ja904472z ↗
6. Hadjipanayis CG, Bonder MJ, Balakrishnan S, Wang X, Mao H, Hadjipanayis GC (2008) Small 4:1925–192910.1002/smll.200800261 ↗
7. Hsiao J-K, Tsai C-P, Chung T-H, Hung Y, Yao M, Liu H-M, Mou C-Y, Yang C-S, Chen Y-C, Huang D-M (2008) Small 4:1445–145210.1002/smll.200701316 ↗
8. Zheng J, Jaffray D, Allen C (2009) Mol Pharm 6:571–58010.1021/mp800234r ↗
9. Kim D, Jeong YY, Jon S (2010) ACS Nano 4:3689–369610.1021/nn901877h ↗
10. Wu W, Li R, Bian X, Zhu Z, Ding D, Li X, Jia Z, Jiang X, Hu Y (2009) ACS Nano 3:2740–275010.1021/nn9005686 ↗
11. Kim D, Park S, Lee JH, Jeong YY, Jon S (2007) J Am Chem Soc 129:7661–766510.1021/ja071471p ↗
12. Glaus C, Rossin R, Welch MJ, Bao G (2010) Bioconjug Chem 21:715–72210.1021/bc900511j ↗
13. Law W-C, Yong K-T, Roy I, Ding H, Hu R, Zhao W, Prasad PN (2009) Small 5:1302–131010.1002/smll.200801555 ↗
14. Yong K-T, Roy I, Ding H, Bergey EJ, Prasad PN (2009) Small 5:1997–200410.1002/smll.200900547 ↗
15. Erogbogbo F, Yong K-T, Roy I, Xu G, Prasad PN, Swihart MT (2008) ACS Nano 2:873–87810.1021/nn700319z ↗
16. Félidj N, Laurent G, Grand J, Aubard J, Lévi G, Hohenau A, Aussenegg F, Krenn J (2006) Plasmonics 1:35–3910.1007/s11468-005-9004-1 ↗
17. Emerich DF (2005) Expert Opin Biol Ther 5:1–510.1517/14712598.5.1.1 ↗
18. Sullivan DC, Ferrari M (2004) Nanotechnology and tumor imaging: seizing an opportunity. In: Molecular imaging, B.C. Decker Inc10.1162/15353500200404139 ↗
19. Weissleder R (2001) Nat Biotech 19:316–31710.1038/86684 ↗
20. Law W-C, Yong K-T, Roy I, Xu G, Ding H, Bergey EJ, Zeng H, Prasad PN (2008) J Phys Chem C 112:7972–797710.1021/jp712090y ↗
21. Kumar R, Nyk M, Ohulchanskyy TY, Flask CA, Prasad PN (2009) Adv Funct Mater 19:853–85910.1002/adfm.200800765 ↗
22. Yong KT (2009) Nanotechnology 20:1510210.1088/0957-4484/20/1/015102 ↗
23. Sokolov K, Follen M, Aaron J, Pavlova I, Malpica A, Lotan R, Richards-Kortum R (2003) Cancer Res 63:1999–2004
24. Mitamura K, Imae T (2009) Plasmonics 4:23–3010.1007/s11468-008-9073-z ↗
25. Ghosh P, Han G, De M, Kim CK, Rotello VM (2008) Adv Drug Deliv Rev 60:1307–131510.1016/j.addr.2008.03.016 ↗
26. Huang X, Jain PK, El-Sayed IH, El-Sayed MA (2007) Nanomedicine 2:681–69310.2217/17435889.2.5.681 ↗
27. Stone JW, Sisco PN, Goldsmith EC, Baxter SC, Murphy CJ (2006) Nano Lett 7:116–11910.1021/nl062248d ↗
28. Sonavane G, Tomoda K, Makino K (2008) Colloids Surf, B 66:274–28010.1016/j.colsurfb.2008.07.004 ↗
29. Kopwitthaya A, Yong K-T, Hu R, Roy I, Ding H, Vathy LA, Bergey EJ, Prasad PN (2010) Nanotechnoloy 21:31510110.1088/0957-4484/21/31/315101 ↗
30. Zhu J, Yong K-T, Roy I , Hu R, Ding H, Zhao LL, Swihart MT, He GS, Cui YP, Prasad PN (2010) Nanotechnology 21:28510610.1088/0957-4484/21/28/285106 ↗
31. Law W-C, Yong K-T, Baev A, Hu R, Prasad PN (2009) Opt Express 17:19041–1904610.1364/OE.17.019041 ↗
32. Yong K-T, Swihart M, Ding H, Prasad P (2009) Plasmonics 4:79–9310.1007/s11468-009-9078-2 ↗
33. Jain P, Huang X, El-Sayed I, El-Sayed M (2007) Plasmonics 2:107–11810.1007/s11468-007-9031-1 ↗
34. Sando G, Berry A, Campbell P, Baronavski A, Owrutsky J (2007) Plasmonics 2:23–2910.1007/s11468-006-9021-8 ↗
35. Mustafa D, Yang T, Xuan Z, Chen S, Tu H, Zhang A (2010) Plasmonics 5:221–23110.1007/s11468-010-9141-z ↗
36. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD (2005) Small 1:325–32710.1002/smll.200400093 ↗
37. Ding H, Yong K-T, Roy I, Pudavar HE, Law WC, Bergey EJ, Prasad PN (2007) J Phys Chem C 111:12552–1255710.1021/jp0733419 ↗
38. Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, Kopelman R (2008) Nano Lett 8:4593–459610.1021/nl8029114 ↗
39. Hu R, Yong K-T, Roy I, Ding H, He S, Prasad PN (2009) J Phys Chem C 113:2676–268410.1021/jp8076672 ↗
40. Calzolari A, Finisguerra V, Oliviero I, Deaglio S, Mariani G, Malavasi F, Testa U (2009) Blood Cells, Molecules, and Diseases 42:5–1310.1016/j.bcmd.2008.10.001 ↗
41. Hirsch L, Gobin A, Lowery A, Tam F, Drezek R, Halas N, West J (2006) Ann Biomed Eng 34:15–2210.1007/s10439-005-9001-8 ↗
42. Huang X, Jain P, El-Sayed I, El-Sayed M (2008) Lasers Med Sci 23:217–22810.1007/s10103-007-0470-x ↗
43. Huang H-C, Barua S, Kay DB, Rege K (2009) ACS Nano 3:2941–295210.1021/nn900947a ↗
44. Huang H-C, Rege K, Heys JJ (2010) ACS Nano 4:2892–290010.1021/nn901884d ↗
45. Norman RS, Stone JW, Gole A, Murphy CJ, Sabo-Attwood TL (2007) Nano Lett 8:302–30610.1021/nl0727056 ↗
46. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Mol Pharm 5:505–51510.1021/mp800051m ↗
47. Boyd BJ (2008) Expert Opin Drug Deliv 5:69–8510.1517/17425247.5.1.69 ↗
48. Burtea C, Laurent S, Elst L, Muller RN (2008) Contrast agents: magnetic resonance. Handb Exp Pharmacol 185:135–16510.1007/978-3-540-72718-7_7 ↗
49. Frullano L, Meade T (2007) J Biol Inorg Chem 12:939–94910.1007/s00775-007-0265-3 ↗
50. Lanza GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, Wickline SA (2004) J Nucl Cardiol 11:733–74310.1016/j.nuclcard.2004.09.002 ↗
51. Link S, Burda C, Nikoobakht B, El-Sayed MA (2000) J Phys Chem B 104:6152–616310.1021/jp000679t ↗